A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 in Healthy Subjects
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Vixotrigine (Primary) ; Valproic acid
- Indications Erythromelalgia; Neuropathic pain; Trigeminal neuralgia
- Focus Pharmacokinetics
- Sponsors Biogen
- 31 Aug 2022 Results evaluating the effects of a uridine diphosphate-glucuronosyltransferase inhibitor, valproic acid, on vixotrigine pharmacokinetics, published in the Clinical Drug Investigation
- 04 Jan 2018 New trial record